London, United Kingdom · Founded 2020 · Privately Held (backing)
Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions. Purespring Therapeutics is based in London, United Kingdom and was founded in 2020. Its last known valuation is $81.6 million. It has raised $165 million.
Last price · $/share
—
Implied valuation
$81.6M
Total raised
$164.7M
Last round
—
Cap table — not yet on record
Purespring Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Purespring Therapeutics with a free account
·Watch Purespring Therapeutics: the Monday email on marks, rounds and moves
